Trial Profile
A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2023
Price :
$35
*
At a glance
- Drugs MK-4830 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Lenvatinib; Paclitaxel; Pemetrexed
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Malignant-mesothelioma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms MK-4830-001
- Sponsors Merck Sharp & Dohme Corp.
- 06 Nov 2023 Planned End Date changed from 4 Sep 2025 to 25 Oct 2025.
- 06 Nov 2023 Planned primary completion date changed from 4 Sep 2025 to 25 Oct 2025.
- 09 Oct 2023 Planned End Date changed from 4 Nov 2025 to 4 Sep 2025.